136
Participants
Start Date
February 12, 2018
Primary Completion Date
September 19, 2019
Study Completion Date
August 24, 2022
Atezolizumab
1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
Obinutuzumab
1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
Venetoclax
800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
Institut Paoli Calmettes, Marseille
CHU de Caen, Caen
CHU de Dijon, Dijon
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse
CHU de Montpellier, Montpellier
CHU de Rennes - Hôpital de Pontchaillou, Rennes
CHRU de Tours, Tours
CHU de Grenoble, La Tronche
CHU de Nantes, Nantes
CHU d'Angers, Angers
CHU de Nancy - Brabois, Nancy
CHRU de Lille, Lille
CHU de Nice, Nice
CHU de Clermont Ferrand - Estaing, Clermont-Ferrand
CHRU de Strasbourg, Strasbourg
Centre Léon Bérard, Lyon
CHU Lyon Sud, Pierre-Bénite
CH Annecy Gennevois, Épagny
Hôpital Saint Louis, Paris
Hôpital Necker, Paris
Centre Henri Becquerel, Rouen
CHD de Vendée, La Roche-sur-Yon
CHU de Poitiers, Poitiers
Institut Curie - Hôpital René Huguenin, Saint-Cloud
Hopital Henri Mondor, Créteil
The Lymphoma Academic Research Organisation
OTHER